Clinical benefit of angiotensin-converting enzyme inhibitors in chronic heart failure

Journal of Cardiovascular Pharmacology

Volumn 27, Issue SUPPL. 2, 1996, Pages

  Kiowski, Wolfgang ^a   Sütsch, Gabor ^a   Dössegger, Lucette ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Angiotensin converting enzyme inhibitors; Cilazapril; Exercise tolerance; Heart failure; Mortality

Indexed keywords

CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ATHEROSCLEROSIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; EXERCISE TOLERANCE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS;

EID: 0029994935     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199600002-00005     Document Type: Conference Paper

References (33)

1. Kluger J, Cody RJ, Laragh JH. The contributions of sympathetic tone and the renin-angiotensin system to severe chronic congestive heart failure: response to specific inhibitors (prazosin and captopril). Am J Cardiol 1982;49:1667-74.
2. Kirlin PC, Grekin R, Das S, Ballor E, Johnson T, Pitt B. Neurohumoral activation during exercise in congestive heart failure. Am J Med 1986;81:623-9.
3. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK. Williams GH. Prostaglandins in severe congestive heart failure. Relation to activation of the renin angiotensin system and hyponatremia. N Engl J Med 1984;310:347-52.
4. Francis GS, Benedict C, Johnston DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9.
5. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure [Editorial]. J Am Coli Cardiol 1992;20:248-54.
6. Swartz SL, Williams GH, Hollenberg NK, Moore TJ, Dluhy RG. Converting enzyme inhibition in essential hypertension: the hypotensive response does not reflect only reduced angiotensin II formation. Hypertension 1979;1:106-11.
7. Carbonell LF, Carretero OA, Stewart JM, Scicli AG. Effect of a kinin antagonist on the acute antihypertensive activity of enalaprilat in severe hypertension. Hypertension 1988;11: 239-43.
8. Dzau VJ, Colucci WS, Williams GH, Curfman G, Meggs L, Hollenberg NK. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. N Engl J Med 1980;302:1373-9.
9. Webster MW, Fitzpatrick MA, Hamilton EJ, et al. Effects of enalapril on clinical status, biochemistry, exercise performance and haemodynamics in heart failure. Drugs 1985;1: 74-81.
10. Cleland JG. The renin-angiotensin system in heart failure. Herz 1991;16:68-81.
11. Sigurdsson A, Amtorp O, Gundersen T, Nilsson B, Remes J, Swedberg K. Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group. Br Heart J 1994; 72:422-7.
12. Wilson JR, Ferraro N. Effect of the renin-angiotensin system on limb circulation and metabolism during exercise in patients with heart failure. J Am Coll Cardiol 1985;6:556-63.
13. Drexler H, Banhardt V, Meinertz T, Wollschläger H, Just H. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. Circulation 1989;79:491-502.
14. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983;2:755-63.
15. Dossegger L, Aldor E, Baird MG, et al. Influence of angiotensin converting enzyme inhibition on exercise performance and clinical symptoms in chronic heart failure: a multicentre, double-blind, placebo-controlled trial. Eur Heart J 1993; 14(suppl):18-23.
16. The Cilazaprl-Captopril Multicenter Group. Comparison of cilazapril and captopril on exercise testing versus placebo in CHF patients. Cardiology 1995;86(suppl 1):34-40.
17. Hedges LV, Olkin I. Statistical methods for meta-analysis. Academic Press, 1985.
18. Cleland JG, Dargie HJ, Ball SG, et al. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J 1985;54:305-12.
19. Chalmers JP, West MJ, Cyran J, et al. Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study. J Cardiovasc Pharmacol 1987;9(suppl 3):S89-97.
20. The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988;259: 539-44.
21. Giles TD, Fisher MB, Rush JE. Lisinopril and captopril in the treatment of heart failure in older patients. Comparison of a long- and short-acting angiotensin-converting enzyme inhibitor. Am J Med 1988;85(suppl 3B):44-7.
22. Lewis GR. Lisinopril versus placebo in older congestive heart failure patients. Am J Med 1988;85(suppl 3B):48-54.
23. Barabino A, Galbariggi G, Pizzorni C, Lotti G. Comparative effects of long-term therapy with captopril and ibopamine in chronic congestive heart failure in old patients. Cardiology 1991;78:243-56.
24. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988;319: 80-6.
25. Sharpe N, Smith H, Murphy J, Greaves S, Hart H, Gamble G. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet 1991;337:872-6.
26. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992;86:431-8.
27. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asympatomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
28. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
29. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
30. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
31. The AIRE Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
32. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332:80-5.
33. Kiowski W, Linder L, Kleinbloesem C, van Brummelen P, Buhler FR. Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition. Circulation 1992;85: 1-8.